Oculis Holding Ag's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Oculis Holding Ag's ROA in the fourth quarter of 2025?
Oculis Holding Ag recorded a cumulative net loss of $-150 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -53.26%.

However, within the Healthcare sector 592 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4484.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	141.34 %	124.03 %	77.79 %	124.03 %	1.29 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-150	-128	-128	-120	-120
Return On Assets (TTM)	-53.26 %	-53.75 %	-64.96 %	-70.25 %	-92.43 %
OCS's Total Ranking	# 4484	#	#	#	# 5026
Total Assets (TTM) in million	297	297	236	297	123
Seq. Total Assets Change	-0 %	26.01 %	-20.64 %	141.34 %	-7.17 %
Seq. Net Income Change	-	-	-	-	-

OCS's 5 Years Annual ROA >> Back to OCS Management Effectiveness >> Compare OCS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 249
Sector	# 593
Overall	# 4445

Return On Assets Statistics
High	Average	Low
-41.94 %	-63.62 %	-77.66 %
(Dec 31 2025)		(Dec 31 2023)

News about Oculis Holding Ag Return on Assets ROA

Oculis Strengthens Leadership with the Appointment of Dr. Sharon Klier as Chief Development Officer

Introduction
Oculis Holding AG, a global biopharmaceutical company dedicated to preserving vision and enhancing eye care, has announced the appointment of Dr. Sharon Klier as Chief Development Officer. Dr. Klier brings extensive experience in clinical development, regulatory submissions, and approvals to her new role, where she will be responsible for providing strategic leadership across Oculis ophthalmology pipeline.
Oculis Holding AG s Recent Success and Challenges
Over the past five trading days, Oculis Holding AG s shares have recorded a solid gain of 6.4%. This positive market performance reflects growing confidence in the company s potential and highlights investor optimism about its future prospects.

Oculis Strengthens its Executive Leadership Team with the Appointment of Dr. Snehal Shah as President of Research & Development

Oculis Holding AG, a leading global biopharmaceutical company dedicated to preserving sight and enhancing eye care, has announced the appointment of Dr. Snehal Shah as the President of Research and Development (RandD). With his extensive experience in research, development, and regulatory affairs spanning over two decades, Dr. Shah is poised to lead the company s RandD strategies and drive market authorizations for its pipeline of innovative eye care therapies.
Oculis Holding AG s Current Performance:
While Oculis Holding AG s stock on the NASDAQ is currently trading -3.3% below its 52-week average, it is essential to note that financial performance alone does not reflect the company s true potential. It is crucial to focus on the strategic initiatives and leadership appointments that contribute to the long-term growth of the organization.

Financial Statements
Oculis Holding Ag's Assets	$ 297 million	OCS's Balance sheet
Oculis Holding Ag's Income	$ -119 million	Quarterly OCS's Income Statement
OCS's Income by Division		See OCS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	FY
Y / Y Total Assets Change	96.06 %	5.25 %	208.56 %	-	-
Total Assets in million	236	120	114	37	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-99	-86	-89	-39	0
Annual Return On Assets	-41.94 %	-71.27 %	-77.66 %	-104.42 %	-

OCS's 5 Years Annual ROA >> Back to OCS Management Effectiveness >> Compare OCS ROA to its Competitors

More Return On Assets Ratios
OCS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
OCS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for OCS's Competitors
Subscribers only: Roa for Oculis Holding Ag's Suppliers
Subscribers only: Return On Assets for OCS's Customers

You may also want to know
OCS's Roi	OCS's Inventory Turnover Ratio	OCS's Growth Rates	OCS's Dividend Comparisons
	OCS's Profitability Ratios	OCS's Asset Turnover Ratio	OCS's Dividend Growth
OCS's Roe	OCS's Valuation Ratios	OCS's Financial Strength Ratios	OCS's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.